Literature DB >> 32040880

Early detection and follow-up of colorectal neoplasia based on faecal volatile organic compounds.

S Bosch1, R Bot1, A Wicaksono2, E Savelkoul1, R van der Hulst3, J Kuijvenhoven3, P Stokkers4, E Daulton2, J A Covington2, T G J de Meij5, N K H de Boer1.   

Abstract

AIM: Early detection and removal of colorectal cancer (CRC) and advanced adenomas (AAs) decreases the incidence of and mortality from the disease. We aimed to evaluate the potential of faecal volatile organic compounds (VOCs) for detection and follow-up of colorectal adenoma using advanced electronic nose technology.
METHOD: This was a prospective multi-centre case-control cohort including two district hospitals and one tertiary referral hospital. Patients undergoing colonoscopy were instructed to collect a faecal sample prior to bowel cleansing and were included in the study when CRC, AAs, large adenomas (LAs; 0.5-1.0 cm), small adenomas (SAs; 0.1-0.5 cm) or no endoscopic abnormalities (controls) were observed. Patients undergoing polypectomy and controls were asked for a second sample after 3 months. Faecal VOCs were measured with gas chromatography-ion mobility spectrometry. Random forest, support vector machine, Gaussian process and neural net classification were used to evaluate accuracy.
RESULTS: In total, 14 patients with CRC, 64 with AAs, 69 with LAs, 127 with SAs and 227 controls were included. A second sample was collected from 32 polypectomy patients and 32 controls. Faecal VOCs discriminated CRC and adenomas from control [AUC (95% CI): CRC vs control 0.96 (0.89-1); AA vs control 0.96 (0.93-1); LA vs control 0.96 (0.92-0.99); SA vs control 0.96 (0.94-0.99)]. There were no significant differences between CRC and adenoma groups. Patients with adenomas and controls were discriminated prior to polypectomy, whereas 3 months after polypectomy VOC profiles were similar [T0 adenoma vs control 0.98 (0.95-1); T1 adenoma vs control 0.55 (0.40-0.69)].
CONCLUSIONS: Faecal VOC profiles may be useful for early detection of CRC and adenomas and the timing of polyp surveillance as polypectomy led to a normalization of the VOC profile.
© 2020 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Volatile organic compounds; advanced adenoma; colorectal cancer; eNose; screening; surveillance

Year:  2020        PMID: 32040880     DOI: 10.1111/codi.15009

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  5 in total

1.  Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers.

Authors:  Heena Tyagi; Emma Daulton; Ayman S Bannaga; Ramesh P Arasaradnam; James A Covington
Journal:  Biosensors (Basel)       Date:  2021-11-03

2.  The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma.

Authors:  Sofie Bosch; Animesh Acharjee; Mohammed N Quraishi; Patricia Rojas; Abdellatif Bakkali; Erwin Ew Jansen; Marina Brizzio Brentar; Johan Kuijvenhoven; Pieter Stokkers; Eduard Struys; Andrew D Beggs; Georgios V Gkoutos; Tim Gj de Meij; Nanne Kh de Boer
Journal:  Gut Microbes       Date:  2022 Jan-Dec

3.  Systematic review: non-endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome.

Authors:  Elsa L S A van Liere; Nanne K H de Boer; Evelien Dekker; Monique E van Leerdam; Tim G J de Meij; Dewkoemar Ramsoekh
Journal:  Aliment Pharmacol Ther       Date:  2022-02-18       Impact factor: 9.524

4.  Diagnostic Ability of Volatile Organic Compounds in Digestive Cancer: A Systematic Review With Meta-Analysis.

Authors:  Hang Yang; Yi Mou; Bing Hu
Journal:  Clin Med Insights Oncol       Date:  2022-06-20

Review 5.  Are Volatile Organic Compounds Accurate Markers in the Assessment of Colorectal Cancer and Inflammatory Bowel Diseases? A Review.

Authors:  Filippo Vernia; Marco Valvano; Stefano Fabiani; Gianpiero Stefanelli; Salvatore Longo; Angelo Viscido; Giovanni Latella
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.